Clinical Research Directory
Browse clinical research sites, groups, and studies.
SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy
Sponsor: Yale University
Summary
The purpose of this study is to longitudinally characterize and evaluate changes in synaptic density in the brain using novel positron-emission tomography (PET) scans; magnetic resonance imaging (MRI), and clinical laboratory markers associated with HIV-related injury in the central nervous system. This study will test hypotheses relating to the presence and mechanisms of aberrant brain structure at the synaptic level in living humans with virologically controlled HIV on antiretroviral therapy. To evaluate associations between PET imaging radiotracers \[11C\]UCB-J, a ligand for presynaptic vesicle protein 2A (SV2A), a vesicle membrane protein expressed in synapses, and PET \[11C\]PBR28 a measure of microglia function in the brain, the Yale PET center has developed an advanced approach of combining multiple distinct ligands in coordinated same-day PET imaging. Additionally, the study will evaluate the associations of this novel synaptic density marker with well-established clinical measures of neurocognitive performance and laboratory measures of blood and cerebrospinal fluid (CSF).
Official title: PET Imaging of Synaptic Density Combined With Neuroimmunologic Measures to Reveal Mechanisms of HIV Neuropathogenesis During ART
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
70
Start Date
2023-05-17
Completion Date
2030-12
Last Updated
2025-09-09
Healthy Volunteers
Yes
Interventions
SV2A PET
SV2A PET scan with radiotracer \[11C\]UCB-J for imaging synaptic density in the brain
TSPO PET
TSPO PET scan with radiotracer \[11C\]PBR28 for imaging of neuroimmune status
Locations (1)
Yale School of Medicne, Neuro ID Research Program
New Haven, Connecticut, United States